Visudyne Gets Medicare Cmte. Recommendation For Occult Lesion Coverage
Executive Summary
CMS should consider limiting Medicare coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) for age-related macular degeneration and occult lesions with no classic choroidal neovascularization to patients with small lesions, members of a Medicare advisory panel said